Basis: Current FMP quote-based enterprise value / four-quarter operating income. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBIT ratio is N/A as of 2026-10-06T19:37:39.249Z.
Calculation as of: 2026-10-06T19:37:39.249Z.
Quote observation: 2026-10-06T19:33:54.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 2d3a9198413857e44d8ff08287218970dc762668c083e85858692cc7a401d48f
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBIT RATIO
N/A
Neonc Technologies Holdings, Inc.
Market Cap
$76.24M
EV/EBIT Ratio
N/A
| NAME | MARKET CAP | EV/EBIT RATIO |
|---|---|---|
| Neonc Technologies Holdings, Inc. (NTHI) | $76.24M | N/A |
| SkinHealth Systems Inc. (SKIN)vs › | $76.45M | N/A |
| Citius Oncology, Inc. (CTOR)vs › | $79.06M | N/A |
| Sera Prognostics, Inc. (SERA)vs › | $77.15M | N/A |
| Pulmonx Corporation (LUNG)vs › | $74.97M | N/A |
| Outset Medical, Inc. (OM)vs › | $77.49M | N/A |
| Inovio Pharmaceuticals, Inc. (INO)vs › | $78.07M | N/A |
| Hyperfine, Inc. (HYPR)vs › | $73.73M | N/A |
| vTv Therapeutics Inc. (VTVT)vs › | $78.44M | N/A |
| Acrivon Therapeutics, Inc. Common Stock (ACRV)vs › | $79.83M | N/A |
EV/EBIT = Enterprise Value / EBIT (TTM)
Enterprise value to EBIT compares total company value to operating earnings, accounting for depreciation unlike EV/EBITDA.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
